Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Incyte Files for U.S. Approval of Cancer Drug

By Drug Discovery Trends Editor | June 8, 2011

NEW YORK (AP) – Incyte Corp. filed for marketing approval of its lead drug candidate ruxolitinib, and has asked regulators to make a decision on the cancer treatment by early December.

The company said on June 6 that it asked the FDA to approve ruxolitinib as a treatment for myelofibrosis, a cancer of the blood. Incyte requested a priority review, and if the FDA grants that review, it will return a decision in six months instead of the usual 10 months. Priority reviews are given to drugs that treat diseases with limited or no treatment options, and Incyte said there are no drugs approved to treat myelofibrosis.

Novartis AG, Incyte’s partner on the drug, has said it will file for approval in the European Union by the end of June.

The company also reported new data from late-stage trials of ruxolitinib at the American Society of Clinical Oncology conference earlier this month. Analysts said on June 7 that the details are encouraging: Anemia has been one of the most common side effects of ruxolitinib in clinical trials, but Incyte said the rates of severe anemia went down over time. After 24 weeks of treatment, patients on ruxolitinib were about as likely to have severe anemia as patients who were only receiving standard treatments.

Thomas Wei, a Jefferies & Co. analyst, said the rates of anemia are high, but patients who were treated with ruxolitinib were less likely to need blood transfusions than other patients. He added that patients who had severe anemia still had strong improvement in their symptoms.

The initial results from the trials were reported in December and March.

The Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE